Proceedings of the National Academy of Sciences · 1991 · 214 citations · 21 references
MedicineNeurosciencePharmacologyBehavioral NeuroscienceNeuropharmacologyPsychopharmacologyAnxiety DisordersAnxiety SymptomsAnxiolytic PharmacologyFear CircuitsNeuroendocrine PharmacologyAnxiolytic ActionCholecystokinin PharmacologyNeuropeptide AntagonistsPharmacologic AnxiolysisPreclinical Anxiety Models
The effect of neuropeptide cholecystokinin (CCK) receptor agonists and antagonists was examined in the rat elevated X-maze model of anxiety. The selective CCK-B receptor antagonists CI-988 (PD 134308) and L-365,260 produced anxiolytic-like effects, whereas MK-329, a CCK-A receptor antagonist, was respectively less potent by factors of 313 and 200. The intracerebroventricular administration of the nonselective CCK receptor agonist caerulein or the selective CCK-B receptor agonist pentagastrin increased dose dependently the level of anxiety. CI-988 dose dependently antagonized the anxiogenic response to pentagastrin but not that induced by pentylenetetrazol. These results strongly suggest that activation of the brain CCK-B receptor induces anxiety and that selective antagonists of this receptor represent a separate class of anxiolytic agents.
21
Jae Hwa Lee, Sung-Young Kim, Young Kyu Kwon et al. · Cellular Physiology and Biochemistry · 2013 · 1.4K citations · Full text
New peptide in the vertebrate CNS reacting with antigastrin antibodies
J.J. Vanderhaeghen, J. C. SIGNEAU, W Gepts · Nature · 1975 · 759 citations
Péter Somogyi, AJ Hodgson, A. David Smith et al. · Journal of Neuroscience · 1984 · 729 citations · Full text